Logo Medical Data Models (MDM) Portal Logo Westfälische Wilhelms-Universität (WWU)
Information:
Error:
en ▾
  • Deutsch
  • English
  • Español
  • Italiano
  • Français
  • Português
  • Svenska
  • Nederlands
  • Login
  • Register
  • Search
  • ODM-XML file upload
  • Create data model
  • ODM-Edit tool
  • Metadata Registry
  • Help
  • About the MDM portal
  • Imprint
  • Login
  • Register
Actions ▾
  • ODM-XML file upload
  • Create data model
  • ODM-Edit tool
  • Metadata Registry
  • About the MDM portal
en ▾
  • Deutsch
  • English
  • Español
  • Italiano
  • Français
  • Português
  • Svenska
  • Nederlands

Search through specific fields of a model

The name of the data model contains study:
name:"study"
The description contains two terms:
description:"double blind"
The copyrightholder contains the term UKM:
copyrightholder:"UKM"
The uploader of the model is Martin Dugas:
uploader:"Martin Dugas"
The keywords contain cancer:
keyword:"cancer"

Refine the search with search operators

Search for groups of words with quotes:
"leukemia myeloid"
Use a wildcard to search for prefixes:
NCT*
With AND/OR/NOT find study without eye nor ear:
study AND NOT (eye OR ear)
Cancer must (+) occur, study not (-):
+cancer -study
You may connect the different search techniques:
name:"form*" AND routine
  • Filter search results
Keywords
Eligibility Determination ×
Ovarian Neoplasms ×
  • Clinical Trial  (29)
  • Gynecology  (21)
  • Fallopian Tube Neoplasms  (9)
  • Medical Oncology  (9)
  • Peritoneal Neoplasms  (8)
  • Disease Status  (4)
  • Laboratories  (4)
  • Drugs, Investigational  (3)
  • Vital Signs  (3)
  • Non Small Cell Lung Cancer  (2)
  • Prostatic Neoplasms  (1)
  • Colorectal Neoplasms  (1)
  • Pulmonary Medicine  (1)
  • Endometrial Neoplasms  (1)
  • Chemotherapy, Adjuvant  (1)
  • Clinical Trial, Phase II  (1)
  • Carcinoma, Squamous Cell  (1)
  • Gastroenterology  (1)
  • Head and Neck Neoplasms  (1)
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
  • Select data models
Selected data models

You must log in to select data models for download or further analysis.

29 Search results.

Sort (Relevance) ▾
  • Relevance
  • Rating
  • New first
  • Old first

Intravenous Topotecan and Gemcitabine as Second-line Treatment in Patients With Ovarian Cancer NCT00061308 - Course -- (Day 1) - Eligibility; Vital Signs; Administration of Study Medications

- 9/2/19 - 1 form, 6 itemgroups, 45 items, 1 language
Itemgroups: Administrative, Eligibility, Vital Signs, Administration of Study Medications, Topotecan Administration, Gemcitabine Administration
Study ID: 104864/627 Clinical Study ID: 104864/627 Study Title: An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00061308 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan, Gemcitabine Study Indication: Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer
  • Eligibility Determination
  • Vital Signs
  • Medical Oncology
  • Clinical Trial
  • Peritoneal Neoplasms
  • Ovarian Neoplasms
  • Gynecology
  • Fallopian Tube Neoplasms
  • Drugs, Investigational

Intravenous Topotecan and Gemcitabine as Second-line Treatment in Patients With Ovarian Cancer NCT00061308 - Course -- Prior to next Course (Day 25 - 28) - Review of Disease Status; Therapeutic Interventions; End of Course Eligibility; Unscheduled Laboratory Tests; Therapeutic Interventions Log

- 9/2/19 - 1 form, 7 itemgroups, 23 items, 1 language
Itemgroups: Administrative, Review of Disease Status, Therapeutic Interventions, End of Course Eligibility, Unscheduled Laboratory Tests - Hematology, Unscheduled Laboratory Tests - Hematology, Therapeutic Interventions
Study ID: 104864/627 Clinical Study ID: 104864/627 Study Title: An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00061308 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan, Gemcitabine Study Indication: Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer
  • Peritoneal Neoplasms
  • Laboratories
  • Medical Oncology
  • Gynecology
  • Disease Status
  • Clinical Trial
  • Eligibility Determination
  • Ovarian Neoplasms
  • Fallopian Tube Neoplasms

Intravenous Topotecan and Gemcitabine as Second-line Treatment in Patients With Ovarian Cancer NCT00061308 - Course 3 Prior to next Course (Day 25 - 28) - Review of Disease Status; Therapeutic Interventions; End of Course Eligibility; Unscheduled Laboratory Tests; Therapeutic Interventions Log

- 9/1/19 - 1 form, 7 itemgroups, 22 items, 1 language
Itemgroups: Administrative, Review of Disease Status, Therapeutic Interventions, End of Course Eligibility, Unscheduled Laboratory Tests - Hematology, Unscheduled Laboratory Tests - Hematology, Therapeutic Interventions
Study ID: 104864/627 Clinical Study ID: 104864/627 Study Title: An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00061308 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan, Gemcitabine Study Indication: Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer
  • Eligibility Determination
  • Medical Oncology
  • Clinical Trial
  • Laboratories
  • Fallopian Tube Neoplasms
  • Disease Status
  • Gynecology
  • Peritoneal Neoplasms
  • Ovarian Neoplasms

Intravenous Topotecan and Gemcitabine as Second-line Treatment in Patients With Ovarian Cancer NCT00061308 - Course 3 (Day 1) - Eligibility; Vital Signs; Administration of Study Medications

- 9/1/19 - 1 form, 6 itemgroups, 44 items, 1 language
Itemgroups: Administrative, Eligibility, Vital Signs, Administration of Study Medications, Topotecan Administration, Gemcitabine Administration
Study ID: 104864/627 Clinical Study ID: 104864/627 Study Title: An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00061308 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan, Gemcitabine Study Indication: Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer
  • Gynecology
  • Eligibility Determination
  • Vital Signs
  • Medical Oncology
  • Peritoneal Neoplasms
  • Drugs, Investigational
  • Clinical Trial
  • Ovarian Neoplasms
  • Fallopian Tube Neoplasms

Intravenous Topotecan and Gemcitabine as Second-line Treatment in Patients With Ovarian Cancer NCT00061308 - Course 2 Prior to next Course (Day 25 - 28) - Review of Disease Status; Therapeutic Interventions; End of Course Eligibility; Unscheduled Laboratory Tests; Therapeutic Interventions Log

- 8/30/19 - 1 form, 7 itemgroups, 22 items, 1 language
Itemgroups: Administrative, Review of Disease Status, Therapeutic Interventions, End of Course Eligibility, Unscheduled Laboratory Tests - Hematology, Unscheduled Laboratory Tests - Hematology, Therapeutic Interventions
Study ID: 104864/627 Clinical Study ID: 104864/627 Study Title: An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00061308 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan, Gemcitabine Study Indication: Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer
  • Medical Oncology
  • Eligibility Determination
  • Ovarian Neoplasms
  • Disease Status
  • Gynecology
  • Peritoneal Neoplasms
  • Laboratories
  • Clinical Trial
  • Fallopian Tube Neoplasms

Intravenous Topotecan and Gemcitabine as Second-line Treatment in Patients With Ovarian Cancer NCT00061308 - Course 2 (Day 1) - Eligibility; Vital Signs; Administration of Study Medications

- 8/30/19 - 1 form, 6 itemgroups, 44 items, 1 language
Itemgroups: Administrative, Eligibility, Vital Signs, Administration of Study Medications, Topotecan Administration, Gemcitabine Administration
Study ID: 104864/627 Clinical Study ID: 104864/627 Study Title: An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00061308 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan, Gemcitabine Study Indication: Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer
  • Gynecology
  • Medical Oncology
  • Drugs, Investigational
  • Fallopian Tube Neoplasms
  • Ovarian Neoplasms
  • Vital Signs
  • Clinical Trial
  • Peritoneal Neoplasms
  • Eligibility Determination

Intravenous Topotecan and Gemcitabine as Second-line Treatment in Patients With Ovarian Cancer NCT00061308 - Course 1 Prior to next Course (Day 25 - 28) - Review of Disease Status; Therapeutic Interventions; End of Course Eligibility; Unscheduled Laboratory Tests; Therapeutic Interventions Log

- 8/30/19 - 1 form, 7 itemgroups, 22 items, 1 language
Itemgroups: Administrative, Review of Disease Status, Therapeutic Interventions, End of Course Eligibility, Unscheduled Laboratory Tests - Hematology, Unscheduled Laboratory Tests - Hematology, Therapeutic Interventions
Study ID: 104864/627 Clinical Study ID: 104864/627 Study Title: An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00061308 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan, Gemcitabine Study Indication: Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer
  • Eligibility Determination
  • Disease Status
  • Peritoneal Neoplasms
  • Ovarian Neoplasms
  • Laboratories
  • Gynecology
  • Clinical Trial
  • Medical Oncology
  • Fallopian Tube Neoplasms

Intravenous Topotecan and Gemcitabine as Second-line Treatment in Patients With Ovarian Cancer NCT00061308 - Eligibility Criteria

- 8/20/19 - 1 form, 3 itemgroups, 22 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria, Did the patient meet all inclusion and exclusion criteria?
Study ID: 104864/627 Clinical Study ID: 104864/627 Study Title: An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00061308 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan, Gemcitabine Study Indication: Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer
  • Fallopian Tube Neoplasms
  • Ovarian Neoplasms
  • Eligibility Determination
  • Peritoneal Neoplasms
  • Medical Oncology
  • Clinical Trial

Topotecan (HycamtinTM) with Carboplatin as First-Line Chemotherapy in Patients with Ovarian Cancer; 104864/612 - Eligibility Determination

- 8/11/19 - 1 form, 3 itemgroups, 18 items, 1 language
Itemgroups: Administrative documentation, Inclusion, Exclusion Criteria
Study ID: 104864/612 Clinical Study ID: 104864/612 Study Title: A Prospective, Open Label Phase II Study to Evaluate the Efficacy and Safety of Topotecan (HycamtinTM) in Combination with Carboplatin as First-line Chemotherapy in Patients with Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan Trade Name: HycamtinTM Study Indication: Ovarian Cancer
  • Clinical Trial
  • Eligibility Determination
  • Ovarian Neoplasms
  • Gynecology
  • Medical Oncology

Predictors of Therapeutic Response in Ovarian Carcinoma NCT01391351 - Eligibility Criteria

- 6/23/19 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Search for Predictors of Therapeutic Response in Ovarian Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT01391351 In order to search for predictors of response to chemotherapy in patients with ovarian carcinoma of the ovary, the fallopian tube or peritoneal serous-type advanced stage, we will define the comparative profiles of miRNA expression of serum polymorphisms and determine differential in 2 patient populations (with or without recurrence 6 months after completion of chemotherapy) with (i) the miRNA profile of serum before treatment and (ii) identification of polymorphisms or SNP (Single Nucleotide Polymorphism) in particular genes involved in the metabolism of chemotherapy agents In the case of miRNA, expression profiles will also be studied during the first course in response to chemotherapy. Indeed, the miRNA profile of serum may be different at baseline among the 2 types of populations (or non-recurrence at 6 months).
  • Clinical Trial
  • Ovarian Neoplasms
  • Chemotherapy, Adjuvant
  • Eligibility Determination

Eligibility Ovarian Carcinoma NCT02244502

- 6/6/19 - 1 form, 2 itemgroups, 31 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety, Feasibility and Effect of TTFields Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02244502
  • Clinical Trial
  • Ovarian Neoplasms
  • Eligibility Determination
  • Gynecology

Eligibility Ovarian Carcinoma NCT02025985

- 6/5/19 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Phase II Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies & Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02025985
  • Clinical Trial
  • Eligibility Determination
  • Ovarian Neoplasms
  • Gynecology
  • 1
  • 2 (current)
  • 3
  • >

Contact

Institute of Medical Informatics
Director: Prof. Dr. Martin Dugas
Albert-Schweitzer-Campus 1, A11
48149 Münster, Germany
Email : imi@uni-muenster.de

In collaboration with

Logo DFG Logo ERCIS Logo IMI Logo CatRIS Logo ULB Logo IH-D Logo Toolpool Logo EFMI
  • Imprint
  • Disclaimer
  • Data Privacy
© 2021  University of Münster
  • Contact
  • Help
  • Cite

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Login

Forgot password?


Register